JID innovations : skin science from molecules to population health最新文献_第3页

Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica 利用分子网络分析进行药物再利用，发现Jak是坏死性类脂质病的靶向驱动因子

JID innovations : skin science from molecules to population health Pub Date : 2024-06-26 DOI: 10.1016/j.xjidi.2024.100296

Alysia N. Hughes , Xing Li , Julia S. Lehman , Steven A. Nelson , David J. DiCaudo , Rekha Mudappathi , Angelina Hwang , Jacob Kechter , Mark R. Pittelkow , Aaron R. Mangold , Aleksandar Sekulic

{"title":"Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica","authors":"Alysia N. Hughes , Xing Li , Julia S. Lehman , Steven A. Nelson , David J. DiCaudo , Rekha Mudappathi , Angelina Hwang , Jacob Kechter , Mark R. Pittelkow , Aaron R. Mangold , Aleksandar Sekulic","doi":"10.1016/j.xjidi.2024.100296","DOIUrl":"10.1016/j.xjidi.2024.100296","url":null,"abstract":"<div><div>Drug repurposing is an attractive strategy for therapy development, particularly in rare diseases where traditional drug development approaches may be challenging owing to high cost and small numbers of patients. In this study, we used a drug identification and repurposing pipeline to identify candidate targetable drivers of disease and corresponding therapies through application of causal reasoning using a combination of open-access resources and transcriptomics data. We optimized our approach on psoriasis as a disease model, demonstrating the ability to identify known and, to date, unrecognized molecular drivers of psoriasis and link them to current and emerging therapies. Application of our approach to a cohort of tissue samples of necrobiosis lipoidica (an unrelated; rare; and, to date, molecularly poorly characterized cutaneous inflammatory disorder) identified a unique set of upstream regulators, particularly highlighting the role of IFNG and the Jak–signal transducer and activator of transcription pathway as a likely driver of disease pathogenesis and linked it to Jak inhibitors as potential therapy. Analysis of an independent cohort of necrobiosis lipoidica samples validated these findings, with the overall agreement of drug-matched upstream regulators above 96%. These data highlight the utility of our approach in rare diseases and offer an opportunity for drug discovery in other rare diseases in dermatology and beyond.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 6","pages":"Article 100296"},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142359550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy Guselkumab 与 Secukinumab 对银屑病生物标志物的不同药效学效应与长期疗效相关：ECLIPSE 子研究

JID innovations : skin science from molecules to population health Pub Date : 2024-06-26 DOI: 10.1016/j.xjidi.2024.100297

Andrew Blauvelt , Yanqing Chen , Patrick J. Branigan , Xuejun Liu , Samuel DePrimo , Brice E. Keyes , Monica Leung , Steven Fakharzadeh , Ya-Wen Yang , Ernesto J. Muñoz-Elías , James G. Krueger , Richard G. Langley

{"title":"Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy","authors":"Andrew Blauvelt , Yanqing Chen , Patrick J. Branigan , Xuejun Liu , Samuel DePrimo , Brice E. Keyes , Monica Leung , Steven Fakharzadeh , Ya-Wen Yang , Ernesto J. Muñoz-Elías , James G. Krueger , Richard G. Langley","doi":"10.1016/j.xjidi.2024.100297","DOIUrl":"10.1016/j.xjidi.2024.100297","url":null,"abstract":"<div><p>IL-23 is a cytokine produced by myeloid cells that drives the T helper 17 pathway and plays an essential role in the pathophysiology of plaque psoriasis. IL-23 activation initiates a cascade of cytokines subsequently inducing the expression of many psoriasis-related proteins. This study aimed to better understand the underlying mechanisms driving the differences between IL-23 and IL-17A blockade in patients with psoriasis and their implications for durability of clinical responses. Serum and/or skin biopsies were isolated from patients treated with guselkumab or secukinumab for evaluation of potential biomarkers of pharmacodynamic response to treatment. Guselkumab treatment led to significantly greater reductions of IL-17F and IL-22 serum levels than treatment with secukinumab at weeks 24 and 48, demonstrating sustained regulation of the IL-23/T helper 17 pathway. Analyses of proteomic and transcriptomic profiles of patient sera and skin biopsies demonstrated differential regulation of proteins involved in chemokine, TNF, and relevant immune signaling pathways to a greater degree with guselkumab than with secukinumab treatment. These data provide insights into the differences between the mechanisms and impact of IL-23 and IL-17A blockade in psoriasis, with implications for efficacy observations and treatment paradigms. Trial Registration: The original study was registered at <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (NCT03090100).</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 5","pages":"Article 100297"},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000444/pdfft?md5=01db74f44a90f4fcecc903affcff3cfb&pid=1-s2.0-S2667026724000444-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141979729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey 银屑病关节炎患者无法接受的症状状态的发生率和影响：全国银屑病基金会2019年度调查结果

JID innovations : skin science from molecules to population health Pub Date : 2024-06-06 DOI: 10.1016/j.xjidi.2024.100292

{"title":"Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey","authors":"","doi":"10.1016/j.xjidi.2024.100292","DOIUrl":"10.1016/j.xjidi.2024.100292","url":null,"abstract":"<div><p>The National Psoriasis Foundation surveyed a random, stratified sample of individuals with psoriatic disease in the United States to determine the prevalence of an unacceptable psoriatic arthritis (PsA) symptom state and its effect on depression and social participation. Acceptable and unacceptable levels of PsA were defined using established cutoff points (acceptable ≤4 vs unacceptable >4) on the Psoriatic Arthritis Impact of Disease 9. Psoriasis severity was defined by body surface area: mild < 3%, moderate–severe ≥ 3%. Depression was assessed utilizing the Patient Health Questionnaire 2. Social participation was assessed by the Patient Reported Outcome Information Measurement System Ability to Participate in Social Role and Activities-SF4a. The analysis cohort comprised 801 patients with PsA. Unacceptable disease activity level (Psoriatic Arthritis Impact of Disease >4) was reported by 59.6% of participants. After adjusting for age, sex, and psoriasis severity, individuals with likely depression (OR = 0.014, <em>P</em> < .001) and those with limited ability to participate in social roles and activities (OR = 0.05, <em>P</em> < .001) were less likely to experience acceptable levels of PsA activity. Ultimately, the results demonstrated that most United States patients with PsA have unacceptable levels of disease activity, which is associated with increased prevalence of depression and limitations in social participation.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 5","pages":"Article 100292"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000390/pdfft?md5=848c12c7c5d789c8a2cbee55d431a42a&pid=1-s2.0-S2667026724000390-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141400361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma 手术切除可改变 Notch 信号转导，并可提高 vismodegib 对局部晚期基底细胞癌的疗效

JID innovations : skin science from molecules to population health Pub Date : 2024-06-06 DOI: 10.1016/j.xjidi.2024.100288

{"title":"Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma","authors":"","doi":"10.1016/j.xjidi.2024.100288","DOIUrl":"10.1016/j.xjidi.2024.100288","url":null,"abstract":"<div><p>Smoothened inhibitors, such as vismodegib, exhibit remarkable success in treating patients with locally advanced basal cell carcinoma (LaBCC). Yet, vismodegib efficacy is hindered by notable side effects, which often lead to treatment discontinuation and subsequent relapse in patients with LaBCC. Prolonged remission was previously reported in patients with LaBCCs who underwent surgical debulking before starting vismodegib. In this study, we enrolled 4 patients with LaBCC who underwent debulking followed by vismodegib therapy to assess their clinical outcomes and analyze the cutaneous molecular changes occurring as a result of surgical intervention. After LaBCC debulking, patients underwent a punch biopsy of residual basal cell carcinoma tissue 1 week later. RT-qPCR analysis of 24 Notch and Wnt signaling–associated genes revealed elevated <em>PTCH1</em>, <em>HEY2</em>, <em>LGR6</em>, <em>FZD2</em>, <em>LEF1</em>, <em>ALCAM</em>, and <em>RUNX1</em> expressions in follow-up biopsies compared with those in patient-matched debulked tissue. Immunoblot and immunostaining further confirmed elevated Notch signaling in follow-up biopsy tissue compared with that in patient-matched debulked tumor tissue. Patients 1, 3, and 4 displayed a clinical response to debulking followed by vismodegib, whereas patient 2 was lost to follow-up after debulking. These findings suggest that surgical manipulation of LaBCCs is correlated with molecular alterations in signaling pathways associated with cellular reprogramming.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 5","pages":"Article 100288"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000353/pdfft?md5=8e38d3493d42fc9fadec23a5fb353a36&pid=1-s2.0-S2667026724000353-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141405897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patient: A Systematic Review 免疫抑制患者的转移性皮肤鳞状细胞癌：系统综述

JID innovations : skin science from molecules to population health Pub Date : 2024-06-05 DOI: 10.1016/j.xjidi.2024.100294

{"title":"Metastatic Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patient: A Systematic Review","authors":"","doi":"10.1016/j.xjidi.2024.100294","DOIUrl":"10.1016/j.xjidi.2024.100294","url":null,"abstract":"<div><p>Patients who are immunosuppressed, such as solid organ transplant recipients (SOTRs), are at a higher risk of developing cutaneous squamous cell carcinoma (cSCC). This population is at a higher risk of metastasis and worse disease-specific survival. The objective of this review is to better characterize the immunosuppressed population with metastatic cSCC. A literature search was conducted to identify reports of lymphatic metastases in immunosuppressed patients with cSCC. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed during creation of a cohort with desired inclusion and exclusion criteria. One hundred and thirty-five articles met the inclusion/exclusion criteria, yielding 1020 total cases. We discovered that the most common forms of immunosuppression within the cohort were solid organ transplantation and hematologic malignancy. White males and cSCC tumors involving the head and neck comprised most cases. Using Brigham and Women’s Hospital and Eighth edition of American Joint Committee on Cancer tumor staging criteria, we observed a trend toward higher stage tumors in SOTR than in patients with hematologic malignancy. This review confirms that known clinical risk factors for metastatic cSCC appear to be similar among the immunosuppressed population and the cSCC population at large. Interestingly, our data suggest that current staging systems may not accurately reflect metastatic risk among patients with hematologic malignancy.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 5","pages":"Article 100294"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000419/pdfft?md5=69c95570f1b3b57d39721c9bab2639e4&pid=1-s2.0-S2667026724000419-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141397624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of the Neurotrophin Network in Skin Squamous Cell Cancer and the Novel Use of the Zebrafish System 神经营养素网络在皮肤鳞状细胞癌中的作用以及斑马鱼系统的新应用

JID innovations : skin science from molecules to population health Pub Date : 2024-06-05 DOI: 10.1016/j.xjidi.2024.100295

Marika Quadri , Elisabetta Palazzo

{"title":"The Role of the Neurotrophin Network in Skin Squamous Cell Cancer and the Novel Use of the Zebrafish System","authors":"Marika Quadri , Elisabetta Palazzo","doi":"10.1016/j.xjidi.2024.100295","DOIUrl":"10.1016/j.xjidi.2024.100295","url":null,"abstract":"<div><p>Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent form of skin cancer. An increasing number of cSCCs are associated with dysregulation of key molecules that control skin homeostasis. These observations have increased interest in the role of neurotrophins and their receptors in the pathogenesis of cSCC. They have been demonstrated to have a considerable impact on the aggressiveness potential of skin cancer by both in vitro and in vivo models. In this context, mouse models are classically used to dissect proliferation versus differentiation balance, but they have some limitations in terms of time, space, and costs. Recently, zebrafish models have been implemented as a new tool to obtain information regarding the invasive capacity and metastasis of neoplastic cells. By xenotransplantation technique, cSCC cells from a patient’s biopsy or cell line can be successfully characterized, with or without the presence of genetic manipulation or treatments. In addition, the evaluation of the immune microenvironment contributes to potentially identifying connections and homologies with humans. In this review, we retrace the role of the neurotrophin network in healthy and pathological skin, particularly in cSCC. We review how zebrafish models can be important tools for studying cSCC development, growth, and potential treatments.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 5","pages":"Article 100295"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000420/pdfft?md5=d8e7142288443c85db28eaed341b2084&pid=1-s2.0-S2667026724000420-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141403396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy 与阿达木单抗相比，古舍库单抗更能降低银屑病患者的疾病和机制相关生物标记物：VOYAGE 1 子研究

JID innovations : skin science from molecules to population health Pub Date : 2024-06-05 DOI: 10.1016/j.xjidi.2024.100287

{"title":"Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy","authors":"","doi":"10.1016/j.xjidi.2024.100287","DOIUrl":"10.1016/j.xjidi.2024.100287","url":null,"abstract":"<div><h3>Background</h3><p>Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses. Selective blockade of IL-23p19 with guselkumab was superior to blockade of TNF-α with adalimumab (ADA) in treating moderate-to-severe psoriasis. Objective: Pharmacodynamic responses of guselkumab versus ADA were compared in patients with psoriasis in VOYAGE 1.</p></div><div><h3>Design</h3><p>Inflammatory cytokine serum levels were assessed (n = 118), and lesional and nonlesional skin biopsies were collected (n = 38) in patient subsets at baseline and 4, 24, and 48 weeks after treatment to evaluate pharmacodynamic responses of guselkumab versus those of ADA.</p></div><div><h3>Results</h3><p>Guselkumab provided rapid reductions in serum IL-17A, IL-17F, and IL-22 levels by week 4 versus at baseline, which were maintained through weeks 24 and 48 (<em>P</em> < .001). The magnitude of reduction of IL-17A and IL-22 at week 48 and IL-17F at weeks 4, 24, and 48 were greater with guselkumab than with ADA (all <em>P</em> < .05). In the skin, guselkumab reduced the expression of IL-23/IL-17 pathway–associated and psoriasis-associated genes.</p></div><div><h3>Conclusion</h3><p>These data provide extensive characterization of pharmacodynamic anti-inflammatory responses to IL-23p19 and TNF-α inhibition in human blood and tissue over time with FDA-approved doses of guselkumab and ADA. <strong>Trial registration:</strong> <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (NCT02207231).</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 5","pages":"Article 100287"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000341/pdfft?md5=e41b338ba36749e6935747be01c4f97d&pid=1-s2.0-S2667026724000341-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141414560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermatologic Considerations for Spaceflight and Space Exploration 太空飞行和太空探索中的皮肤科注意事项

JID innovations : skin science from molecules to population health Pub Date : 2024-05-31 DOI: 10.1016/j.xjidi.2024.100293

Megan Zhao , Haig Aintablian , Robert L. Satcher , Roxana Daneshjou , Misha Rosenbach

引用次数: 0

Factors Associated with Adoption of Immune Checkpoint Inhibitor Treatment for Advanced Melanoma: A SEER-Medicare Cohort Study 采用免疫检查点抑制剂治疗晚期黑色素瘤的相关因素： SEER-医保队列研究

JID innovations : skin science from molecules to population health Pub Date : 2024-05-21 DOI: 10.1016/j.xjidi.2024.100289

Cassandra Mohr , Kaiping Liao , Candice L. Hinkston , Mackenzie R. Wehner , Meng Li

{"title":"Factors Associated with Adoption of Immune Checkpoint Inhibitor Treatment for Advanced Melanoma: A SEER-Medicare Cohort Study","authors":"Cassandra Mohr , Kaiping Liao , Candice L. Hinkston , Mackenzie R. Wehner , Meng Li","doi":"10.1016/j.xjidi.2024.100289","DOIUrl":"10.1016/j.xjidi.2024.100289","url":null,"abstract":"<div><p>We aimed to explore the differences in immune checkpoint inhibitor (ICI) immunotherapy utilization for advanced melanoma by examining patient and neighborhood characteristics. We performed a retrospective cohort study using a deidentified, random sample of SEER-Medicare beneficiaries aged ≥65 years with stage III or stage IV melanoma (2011–2017). Our primary outcome was initiation of ICI immunotherapy (ipilimumab, pembrolizumab, nivolumab, or atezolizumab) after stage III or stage IV melanoma diagnosis. We analyzed ICI usage with multivariable logistic regression. After analyzing the entire 2011–2017 cohort, we conducted a secondary analysis in which we separately analyzed the 2011–2014 and 2015–2017 cohorts to assess possible differences over time. We included 3531 beneficiaries, with mean follow-up of 2.1 (SD = 2.0) years. Higher likelihood of ICI usage was associated with male sex (OR = 1.21, 95% confidence interval = 1.04–1.42) and higher density of medical oncologists (OR = 1.02, 95% confidence interval = 1.01–1.04). Lower likelihood of ICI usage was associated with older age group and Charlson comorbidity score (score ≥2; OR = 0.72, 95% confidence interval = 0.60–0.86). These associations were diminished in more recent years (no association with sex, medical oncologist density, Charlson comorbidity score, and association with only the oldest age group in years 2015–2017). We found significant sex- and age-related differences in initiation among SEER-Medicare beneficiaries with stage III or stage IV melanoma, which appear to be improving over time.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 4","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000365/pdfft?md5=9afd44e58671efdf3c0ed9288dd00f3c&pid=1-s2.0-S2667026724000365-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141134453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNA Signatures Associated with Basal Cell Carcinoma Subtypes 与基底细胞癌亚型相关的微RNA特征

JID innovations : skin science from molecules to population health Pub Date : 2024-05-03 DOI: 10.1016/j.xjidi.2024.100286

Suzanne Fastner , Hafeez Rahman , Jose Gutierrez , Nathan Shen , Scott R. Florell , Abigail Florell , Chris J. Stubben , Kenneth M. Boucher , Dekker C. Deacon , Robert L. Judson-Torres , Douglas Grossman

{"title":"MicroRNA Signatures Associated with Basal Cell Carcinoma Subtypes","authors":"Suzanne Fastner , Hafeez Rahman , Jose Gutierrez , Nathan Shen , Scott R. Florell , Abigail Florell , Chris J. Stubben , Kenneth M. Boucher , Dekker C. Deacon , Robert L. Judson-Torres , Douglas Grossman","doi":"10.1016/j.xjidi.2024.100286","DOIUrl":"10.1016/j.xjidi.2024.100286","url":null,"abstract":"<div><p>Basal cell carcinoma (BCC) is classified histologically into subtypes that determine treatment decisions. MicroRNAs (miRs) are short noncoding RNAs that may serve as diagnostic biomarkers. We investigated if particular miRs could distinguish BCC subtypes. We sequenced miRs from 55 archival BCC and 9 control skin specimens and then validated these miRs by qRT-PCR assay on a second BCC cohort (18 superficial, 16 nodular, 15 infiltrative) and control skin (n = 12). Expression values for individual miRs were normalized to miR-16-5p, which was the least variant among the control skin and BCC samples. We found that (i) miR-383-5p and miR-145-5p are downregulated in all BCC subtypes compared with control skin, (ii) miR-181c-5p is downregulated in superficial compared with invasive (nodular/infiltrative) BCC, and (iii) miR-22-5p and miR-708-5p are upregulated in infiltrative compared with superficial/nodular BCC and miR-30c-5p is downregulated in infiltrative compared with nodular BCC. Receiver operating characteristic analysis demonstrated excellent capacity of these miRs to discriminate between BCC and control skin (area under the curve, 0.94–0.98), whereas the capacity to discriminate between superficial and invasive subtypes was less robust (area under the curve, 0.7–0.8). Future prospective studies may determine the utility of these miRs as diagnostic biomarkers to guide biopsy and treatment of BCC.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 4","pages":"Article 100286"},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266702672400033X/pdfft?md5=5b73694006f30288640b9ea9f57e5331&pid=1-s2.0-S266702672400033X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141035605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0